Trial Profile
An Open-Label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Fosamprenavir (Primary) ; Antiretrovirals; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; ViiV Healthcare
- 05 Jun 2009 New trial record.
- 05 Jun 2009 New source identified and integrated (GlaxoSmithKline Clinical Trials Register).